Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Exelixis, Inc and Prometheus Laboratories Inc.

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASCO: Matching Treatment to Patient in an Ever-Changing Era for the Management of Advanced Renal Cell Carcinoma: An Expert Tumor Board Discussion

ASCO: Matching Treatment to Patient in an Ever-Changing Era for the Management of Advanced Renal Cell Carcinoma: An Expert Tumor Board Discussion


Saturday, June 2, 2018
7:00 PM - 9:00 PM

Dinner and registration: 6:30 PM – 7:00 PM

Hilton Chicago
Salon A 1 & 2 (Lower Level)
720 S Michigan Avenue
Chicago, IL 60605

What You'll Learn:

  • The relevance of biology to mRCC treatment decisions
  • What drives decision to switch RCC therapy
  • How to manage toxicities for patients with RCC

Overview:

Clinical decision- making in the setting of metastatic renal cell carcinoma (RCC) has dramatically changed over the past few years. Recent and pending approvals of new agents and combinations, as well as expanded indications, have raised questions about how rational treatment planning can be used to match the most optimal strategy to the patient. At the same time, accumulating real-world experience with newer agents and emerging trial data continue to refine state-of-the-art care is in RCC. The management of metastatic clear cell RCC (ccRCC) continues to evolve, with multiple treatment options available for patients who relapse following adjuvant surgical and tyrosine kinase inhibitor (TKI) therapy.

This activity is designed to address your key questions related to RCC management via discussion of data and real-world patient cases by a multidisciplinary faculty of internationally recognized experts in RCC. Adverse event management and future directions in the field will also be addressed and considered throughout the program in the context of the program theme, to help you individualize patient care. Foremost, this program aims to provide you with cutting-edge, practical guidance that can be applied immediately to your clinical practice.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Exelixis, Inc and Prometheus Laboratories Inc.

Target Audience

This educational program is directed toward medical oncologists interested in the treatment of renal cell carcinoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with RCC will be invited to participate.

Educational Objectives:

Upon completion of this activity, participants will be able to:

  1. Explain the biology and molecular genetics of RCC and the mechanistic rationale for targeted therapies.
  2. Evaluate practice-changing trials in RCC and potential influence of recent clinical data on multiple lines of treatment for patients with metastatic RCC.
  3. Apply best practices to proactively identify and mitigate treatment-related toxicities in metastatic RCC.
  4. Integrate knowledge of patient characteristics, and single agent and combination strategies to inform treatment decisions that optimize outcomes for patients with metastatic RCC.


Program Chair

Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Director, Kidney Cancer Center
Senior Physician, Dana-Farber Cancer Institute
Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School
Boston, MA

Click to see all our ASCO programs!







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By